BioCentury | Jul 29, 2020
Distillery Therapeutics

Inhibiting proteolytic activation of the receptor PAR2 for eosinophilic esophagitis

...antagonist mAb MEDI0618 in Phase I testing for osteoarthritis pain. TARGET/MARKER/PATHWAY: Kallikrein-related peptidase 5 (KLK5); protease-activated receptor...
...Children’s Hospital Medical Center, Cincinnati, Ohio email: rothenberg@cchmc.org Claire Quang Cincinnati Children's Hospital Medical Center Kallikrein-related peptidase 5 (KLK5) Protease-activated receptor...
BioCentury | Jan 15, 2019
Distillery Therapeutics

Cancer

...reduce thrombotic cardiovascular events after myocardial infarction (MI) or in peripheral arterial disease (PAD). TARGET/MARKER/PATHWAY: Protease-activated receptor...
...2018 doi:10.3389/fneur.2018.01087 CONTACT: Efrat Shavit-Stein, Tel Aviv University, Ramat Gan, Israel email: efrat.shavit.stein@gmail.com Jennie Walters Tel Aviv University Protease-activated receptor...
BioCentury | May 23, 2017
Distillery Techniques

Drug platforms

...to develop PAR2 inhibitors targeting the three identified binding sites. DESCRIPTION: Structural analyses of a protease-activated receptor...
...CONTACT: Fiona Marshall, Heptares Therapeutics Ltd., Welwyn Garden City, U.K. email: fiona.marshall@heptares.com Hongjiang Li AstraZeneca plc Heptares Therapeutics Ltd. Protease-activated receptor...
BioCentury | May 1, 2017
Clinical News

Paper identifies MOA of PAR2 antagonists

...Sosei Group Corp. (Tokyo:4565) and AstraZeneca plc (LSE:AZN; NYSE:AZN) identified the binding mechanism of two protease-activated receptor...
...will allow for further structure-based drug design of PAR2 inhibitors. Mary Romeo AstraZeneca plc Heptares Therapeutics Ltd. Sosei Group Corp. Protease-activated receptor...
BioCentury | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

...pathway could increase differentiation of OPCs to promote remyelination Case Western Reserve University Paul Tesar Protease-activated receptor...
BioCentury | Sep 12, 2016
Company News

Merck, Aralez deal

...Aralez purchased U.S. and Canadian rights to Zontivity vorapaxar from Merck. The protease-activated receptor 1 (PAR1) antagonist...
BioCentury | Aug 22, 2016
Company News

Merck sales and marketing update

...result of the discontinuation, Merck will displace 148 of field-based sales and headquarter-based employees. The protease-activated receptor...
BioCentury | Jul 11, 2016
Clinical News

Zontivity vorapaxar regulatory update

...to include reduction of atherothrombotic events in adults with symptomatic peripheral arterial disease (PAD). The protease-activated receptor...
BioCentury | Aug 27, 2015
Distillery Techniques

Techniques: Atomic force microscopy (AFM) for measuring GPCR-ligand binding in lipid membranes

...in which the extent of deflection corresponds to the force of the binding interaction. For protease-activated receptor...
BioCentury | Mar 2, 2015
Clinical News

Zontivity vorapaxar: Additional Phase III data

...formerly SCH 530348 ) Business: Cardiovascular Molecular target: Protease-activated receptor 1 (PAR1) ; Thrombin receptor Description: Protease-activated receptor...
Items per page:
1 - 10 of 50